These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 19432105)

  • 1. [Osteoclastogenesis and bone resorption].
    Nakamura M; Nakamichi Y; Nakamura H; Udagawa N
    Nihon Rinsho; 2009 May; 67(5):889-96. PubMed ID: 19432105
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [BMP and osteoclastogenesis].
    Nakamura M; Udagawa N; Yamamoto Y; Nakamura H
    Clin Calcium; 2006 May; 16(5):809-15. PubMed ID: 16679623
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A new member of tumor necrosis factor ligand family, ODF/OPGL/TRANCE/RANKL, regulates osteoclast differentiation and function.
    Takahashi N; Udagawa N; Suda T
    Biochem Biophys Res Commun; 1999 Mar; 256(3):449-55. PubMed ID: 10080918
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Osteoclastogenesis Inhibitory Factor (OCIF) /Osteoprotegerin (OPG) as a new therapeutic agent for osteoporosis].
    Mochizuki S; Kiyokawa A; Nagayama Y
    Clin Calcium; 2005 Jan; 15(1):35-42. PubMed ID: 15632471
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Control of bone resorption by RANKL-RANK system].
    Harada S; Takahashi N
    Clin Calcium; 2011 Aug; 21(8):1121-30. PubMed ID: 21814016
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impaired bone resorption in cathepsin K-deficient mice is partially compensated for by enhanced osteoclastogenesis and increased expression of other proteases via an increased RANKL/OPG ratio.
    Kiviranta R; Morko J; Alatalo SL; NicAmhlaoibh R; Risteli J; Laitala-Leinonen T; Vuorio E
    Bone; 2005 Jan; 36(1):159-72. PubMed ID: 15664014
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fibroblastic stromal cells express receptor activator of NF-kappa B ligand and support osteoclast differentiation.
    Quinn JM; Horwood NJ; Elliott J; Gillespie MT; Martin TJ
    J Bone Miner Res; 2000 Aug; 15(8):1459-66. PubMed ID: 10934644
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heparin enhances osteoclastic bone resorption by inhibiting osteoprotegerin activity.
    Irie A; Takami M; Kubo H; Sekino-Suzuki N; Kasahara K; Sanai Y
    Bone; 2007 Aug; 41(2):165-74. PubMed ID: 17560185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Osteoprotegerin and its ligand: A new paradigm for regulation of osteoclastogenesis and bone resorption.
    Aubin JE; Bonnelye E
    Medscape Womens Health; 2000 Mar; 5(2):5. PubMed ID: 10792853
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The molecular mechanism of osteoclastic bone resorption and inhibitory drugs for bone resorption].
    Yamamoto Y; Noguchi T; Udagawa N
    Clin Calcium; 2005 Jul; 15(7):11-6. PubMed ID: 15995290
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Osteoporosis and RANKL signal].
    Nakamura M; Udagawa N
    Clin Calcium; 2011 Aug; 21(8):1149-55. PubMed ID: 21814019
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The OPG/RANKL/RANK system and bone resorptive disease].
    Liu JZ; Ji ZL; Chen SM
    Sheng Wu Gong Cheng Xue Bao; 2003 Nov; 19(6):655-60. PubMed ID: 15971575
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Osteoprotegerin regulates bone formation through a coupling mechanism with bone resorption.
    Nakamura M; Udagawa N; Matsuura S; Mogi M; Nakamura H; Horiuchi H; Saito N; Hiraoka BY; Kobayashi Y; Takaoka K; Ozawa H; Miyazawa H; Takahashi N
    Endocrinology; 2003 Dec; 144(12):5441-9. PubMed ID: 14500574
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alisol-B, a novel phyto-steroid, suppresses the RANKL-induced osteoclast formation and prevents bone loss in mice.
    Lee JW; Kobayashi Y; Nakamichi Y; Udagawa N; Takahashi N; Im NK; Seo HJ; Jeon WB; Yonezawa T; Cha BY; Woo JT
    Biochem Pharmacol; 2010 Aug; 80(3):352-61. PubMed ID: 20412788
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pathways regulating bone formation: a complex network].
    Thomas T; Martin A
    J Soc Biol; 2008; 202(4):257-64. PubMed ID: 19094924
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Cytokine-mediated bone resorption].
    Nakamura M; Uehara S; Nakamura H; Udagawa N
    Clin Calcium; 2014 Jun; 24(6):837-44. PubMed ID: 24870834
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhancement of crude bone morphogenetic protein-induced new bone formation and normalization of endochondral ossification by bisphosphonate treatment in osteoprotegerin-deficient mice.
    Tabuchi M; Miyazawa K; Kimura M; Maeda H; Kawai T; Kameyama Y; Goto S
    Calcif Tissue Int; 2005 Oct; 77(4):239-49. PubMed ID: 16193235
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inflammatory T cells rapidly induce differentiation of human bone marrow stromal cells into mature osteoblasts.
    Rifas L; Arackal S; Weitzmann MN
    J Cell Biochem; 2003 Mar; 88(4):650-9. PubMed ID: 12577299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vitamin D receptor in chondrocytes promotes osteoclastogenesis and regulates FGF23 production in osteoblasts.
    Masuyama R; Stockmans I; Torrekens S; Van Looveren R; Maes C; Carmeliet P; Bouillon R; Carmeliet G
    J Clin Invest; 2006 Dec; 116(12):3150-9. PubMed ID: 17099775
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Microrough implant surface topographies increase osteogenesis by reducing osteoclast formation and activity.
    Lossdörfer S; Schwartz Z; Wang L; Lohmann CH; Turner JD; Wieland M; Cochran DL; Boyan BD
    J Biomed Mater Res A; 2004 Sep; 70(3):361-9. PubMed ID: 15293309
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.